Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]- 1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl ]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity

Neuropharmacology

Volumn 50, Issue 8, 2006, Pages 975-983

  Dawson, Lee A ^a   Hughes, Zoë A ^a   Starr, Kathryn R ^a   Storey, James D ^a   Bettelini, Letizia ^b   Bacchi, Fabrizio ^b   Arban, Roberto ^b   Poffe, Alessandro ^b   Melotto, Sergio ^b   Hagan, James J ^a   Price, Gary W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GSK   (Italy)

Author keywords

5 HT (serotonin); 5 HT1B receptor; Forced swim test; Human threat test; Microdialysis; Pup vocalisation test

Indexed keywords

1 [6 (3,5 DIMETHYLPIPERAZIN 1 YL) 2,3 DIHYDRO 5 METHOXYINDOL 1 YL] 1 [2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)BIPHENYL 4 YL]METHANONE; 3 (2 DIMETHYLAMINOETHYL) 4 CHLORO 5 PROPOXYINDOLE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DIAZEPAM; FLUOXETINE; PAROXETINE; SB 616234A; SEROTONIN 1 AGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BODY POSTURE; CONTROLLED STUDY; DENTATE GYRUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SELECTIVITY; FEMALE; FORCED SWIMMING TEST; GUINEA PIG; HYPOTHERMIA; IMMOBILIZATION; IN VIVO STUDY; MALE; MARMOSET; MATERNAL DEPRIVATION; MICRODIALYSIS; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; VOCALIZATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CALLITHRIX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GUINEA PIGS; HYPOTHERMIA; IMMOBILITY RESPONSE, TONIC; INDOLES; MALE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN ANTAGONISTS; SWIMMING; TIME FACTORS; VOCALIZATION, ANIMAL;

EID: 33747081967     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.01.010     Document Type: Article

References (50)

1. 1F receptors for beta-adrenergic antagonists. Neuropharmacology 33 (1994) 387-391
2. Ahlgren C., Eriksson A., Tellefors P., Ross S.B., Stenfors C., and Malmberg A. In vitro characterisation of AR-A000002, a novel 5-hydroxytryptamine1B autorecpetor antagonist. Eur. J. Pharmacol. 499 (2004) 67-75
3. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
4. Blier P., Serrano A., and Scatton B. Differential responsiveness of the rat dorsal and nedial raphe 5-HT systems on 5-HT1 receptor agonists and p-chloroamphetamine. Synapse 5 (1990) 120-133
5. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1 (1987) 470-480
6. Borsini F., and Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity. Psychopharmacology 94 (1988) 147-160
7. Bourin M., Hascoet M., Colombel M.-C., Redrobe J.P., and Baker G.B. Differential effects of clonidine, lithium, and quinine in the forced swimming test in mice for antidepressants: possible roles of serotonergic systems. Eur. Neuropsychopharmacol. 6 (1996) 231-236
8. Borsini F., Podhorna J., and Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?. Psychopharmacology 163 (2002) 121-141
9. Cesana R., Ceci A., Ciprandi C., and Borsini F. Mesulergine antagonism towards the fluoxetine anti-immobility effects in the forced swimming test in mice. J. Pharm. Pharmacol. 45 (1993) 473-475
10. Costall B., Domeney A.M., Gerrard P.A., and Naylor R.J. A primate model for assessment of anxiolytic drug action. Br. J. Pharmacol. 95 (1988) 475P
11. Cryan J.F., and Lucki I. Antidepressant-like behavioural effects mediated by 5-Hydroxytryptamine (2C) receptors. J. Pharmacol. Exp. Ther. 295 (2000) 1120-1126
12. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 29 (2005) 547-569
13. 1D autoreceptors. Neuropharmacology 35 (1996) 1627-1634
14. Delgado J.M.R., Charney D.S., Price L.H., Aghajanian G.K., Landis H., and Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant - induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Physchiatry. 47 (1990) 411-418
15. Draper N.R., and Smith H. Applied Regression Analysis (1966), John Wiley and Sons, New York NY.
16. Feldberg W., and Myers W.F. Effects on temperature of 5-hydroxtryptamine, adrenaline and noradrenaline injected into the cerebral ventricles of the hypothalamus of cats. J. Physiol. 173 (1964) 25-30
17. Fernstrom J.D., and Wurtman R.J. Brain serotonin content: increase following ingestion of carbohydrate diet. Science 174 (1971) 1023-1025
18. Gardner C.R. Distress vocalization in rat pups a simple screening method for anxiolytic drugs. J. Pharmacol. Methods 14 (1985) 181-187
19. 1B receptor inverse agonist SB-224289-A, potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. Annals N.Y. Acad. Sci. 861 (1998) 270-271
20. Golden R.N., and Gilmore J. Serotonin and mood disorders. Psychiatr. Ann. 20 (1990) 580-586
21. Gorzalka B.B., Mendelson S.D., and Watson N.V. Serotonin receptor subtypes and sexual behaviour. Annals N.Y. Acad. Sci. 600 (1990) 435-446
22. Graeff F.G. On serotonin and experimental anxiety. Psychopharmacology 163 (2002) 467-476
23. 1B receptors cause hypothermia in the guinea-pig. Eur. J. Pharmacol. 331 (1997) 169-174
24. 1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181. Br. J. Pharmacol. 125 (1998) 1733-1743
25. Hoyer D., and Middlemiss D.N. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol. Sci. 13 (1989) 130-132
26. Hudzik T.J., Yanek M., Porrey T., Evenden J., Paronis C., Mastrangelo M., Ryan C., Ross S., and Stenfors C. Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist. J. Pharmacol. Exp. Ther. 304 (2003) 1072-1084
27. Hughes Z.A., and Dawson L.A. Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: species and regional differences. Psychopharmacololgy 172 (2004) 87-93
28. Jouvet M. Neurophysiology of the states of sleep. Physiol. Rev. 47 (1967) 117-177
29. Knobelman D.A., Hen R., and Lucki I. Genetic regulation of extracellular serotonin by 5-hydroxytryptamine (1A) and 5-hydroxytryptamine (1B) autoreceptors in different brain regions of the mouse. J. Pharmacol. Exp. Ther. 298 (2001) 1083-1091
30. 3 receptors in the control of 5-HT release in rat hippocampus in vivo. Br. J. Pharmacol. 106 (1992) 139-142
31. 1B receptors. Annals N.Y. Acad. Sci. 600 (1990) 132-147
32. Middlemiss D.N., Bremer M.E., and Smith S.M. A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig frontal cortex. Eur. J. Pharmacol. 157 (1988) 101-107
33. 1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur. J. Pharmacol. 375 (1999) 359-365
34. Mitchell S.N., Greenslade R.G., and Cooper J. LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat. Eur. J. Pharmacol. 432 (2001) 19-27
35. Moret C., and Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur. J. Pharmacol. 295 (1996) 189-197
36. Moret C., and Briley M. The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. Eur. J. Pharmacol. 404 (2000) 1-12
37. Olivier B., Molewijk H.E., van der Heyden J.A., van Oorschot R., Ronken E., Mos J., and Miczek K.A. Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Neurosci. Biobehav. Rev. 23 (1998) 215-227
38. Porsolt R.D., Bertin A., and Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327-336
39. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
40. Rapisarda C., and Bacchelli B. The brain of the guinea pig in stereotaxic coordinates. Arch. Sci. Biol. 61 (1977) 1-37
41. 1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur. J. Pharmacol. 318 (1996) 213-220
42. 1B receptor selectivity for 5-HT terminal autoreceptor activity: an in vivo microdialysis study in the freely-moving guinea-pig. Neuropharmacology 36 (1997) 549-557
43. Roberts C., Price G.W., and Jones B.J. The role of 5-HT(1B/1D) receptors in the modulation of 5-hydroxytryptamine levels in the frontal cortex of the conscious guinea pig. Eur. J. Pharmacol. 326 (1997) 23-30
44. 1B/1D receptor antagonists in dorsal and median raphe innervated brain regions. Eur. J. Pharmocol. 346 2-3 (1998) 175-180
45. 1A or 5-HT re-uptake site blockade. Neuropharmacology 38 (1999) 1409-1419
46. 1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely moving guinea pig. Naunyn-Schmeideberg's Arch. Pharmacol. 362 (2000) 177-183
47. Roberts C., Price G.W., and Middlemiss D.N. Ligands for the investigation of 5-HT autoreceptor function. Brain Res. Bull. 56 (2001) 463-469
48. Sanchez C., and Meier E. Behavioural profiles of SSRIs in animal models of depression, anxiety and aggression - are they all alike?. Psychopharmacology 129 (1997) 197-205
49. Stenfors C., Hallerback T., Gunnar Larsson L., Wallsten C., and Ross S.B. Pharmacology of a novel selective 5-hydroxytryptamine1B receptor antagonist, AR-A000002. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 330-337
50. Tenen S.S. The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance acquisition, pain sensitivity and related behaviour in the rat. Psychopharmacology 10 (1967) 204-219